Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Diabetes: Management and Pharmacotherapy

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

Acute Pancreatitis II: Clinical Manifestations and Management

Acute Pancreatitis II: Clinical Manifestations and Management

Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...

Overview of Lipid Metabolism

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...

Angina IV: Management

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

European and Canadian derived risk prediction equations for atherosclerotic cardiovascular disease are valid in Australian patients with genetically confirmed familial hypercholesterolaemia.

Atherosclerosis·2026

Same author

Risk factors for atherosclerotic cardiovascular disease in individuals with heterozygous familial hypercholesterolemia: a systematic review and meta-analysis.

Atherosclerosis·2026

Same author

Low-plastic diet and urinary levels of plastic-associated phthalates and bisphenols: the randomized controlled PERTH Trial.

Nature medicine·2026

Same author

The future of triglyceride-regulating therapies and registries.

Current opinion in endocrinology, diabetes, and obesity·2026

Same author

Hypertriglyceridemia: updates from clinical trials of new agents and real-world registries.

Current opinion in endocrinology, diabetes, and obesity·2026

Same author

Association of leukocyte count with atherosclerotic cardiovascular disease in patients with genetically defined familial hypercholesterolaemia.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2025

Search research articles

Related Experiment Video

Updated: May 7, 2026

Assessing Whole-Body Lipid-Handling Capacity in Mice

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

Demystifying the management of hypertriglyceridaemia.

Gerald F Watts¹, Esther M M Ooi, Dick C Chan

¹Lipid Disorders Clinic and Metabolic Research Centre, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, PO Box X2213, Perth, WA 6847, Australia.

Nature Reviews. Cardiology

|September 25, 2013

Summary

Hypertriglyceridaemia, a common risk factor for cardiovascular disease, stems from genetic and lifestyle factors. Management includes lifestyle changes, statins, fibrates, and n-3 fatty acids, with emerging therapies for severe cases.

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Related Experiment Videos

Last Updated: May 7, 2026

Assessing Whole-Body Lipid-Handling Capacity in Mice

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Area of Science:

Cardiovascular Medicine
Metabolic Disorders
Genetics

Background:

Hypertriglyceridaemia is a prevalent risk factor for atherosclerotic cardiovascular disease (CVD).
It is associated with metabolic complications like obesity, insulin resistance, and diabetes mellitus.
Elevated triglycerides reflect an accumulation of proatherogenic lipoproteins, including triglyceride-rich lipoprotein (TRL) remnants.

Purpose of the Study:

To review the causes, consequences, and management of hypertriglyceridaemia.
To discuss the role of TRLs in the pathogenesis of atherosclerotic CVD.
To explore current and emerging therapeutic strategies for hypertriglyceridaemia.

Main Methods:

Review of existing literature on hypertriglyceridaemia, TRL metabolism, and CVD.
Analysis of data from Mendelian randomization studies and clinical trials.
Discussion of genetic dyslipidaemias and their implications.

Main Results:

TRLs are causally linked to atherosclerotic CVD.
Extreme hypertriglyceridaemia (>20 mmol/l) is rare, often genetic, and can cause pancreatitis.
Statins, fibrates, and n-3 fatty acids are key treatments, alongside lifestyle modification.

Conclusions:

Effective management of hypertriglyceridaemia involves addressing secondary factors and lifestyle.
Pharmacotherapy is crucial for high-risk individuals.
Novel therapies targeting TRL metabolism show promise for future treatment.